This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Most Read Pharmaceutical And Health News - January '13

AUSTIN, Texas, Feb. 5, 2013 /PRNewswire/ -- dailyRx News announced today the most popular health topics viewed and shared during January 2013.  dailyRx News publishes and syndicates consumer-centric health information across affiliated websites, YouTube, various news aggregators, and to patients through a national network of healthcare providers' social media channels.

"dailyRx News reports on medication and health research distributed by the FDA, medical schools, and clinical trials," said Donald W. Hackett, CEO and Publisher of dailyRx News. "dailyRx's reporters and medical editors understand the importance of translating medical terminology into information that everyone can understand.  We focus on publishing content that is timely, accurate, and actionable," Hackett added. 

According to the Pew Research Center's Internet & American Life Project, 35% of American adults have searched the web specifically to learn about a medical condition they or someone they know might have. "With an increasing number of Americans accessing digital information for initial self-diagnosis purposes, there is no room in today's news industry for outdated information, biased research, or reader confusion," Hackett said. 

Health conditions generating notable viewer engagement on last month included:

January's most-viewed medications included:

Trending health news throughout dailyRx social media included:

About The dailyRx News Network

The dailyRx News Network is an emerging leader in publishing health news for consumers and patients alike. dailyRx publishes, aggregates, and syndicates doctor-reviewed news covering a wide range of health conditions, medications, over-the-counter products, and nutraceutical compounds. dailyRx's original content is written in positive, unbiased, easy-to-understand language and reviewed for accuracy by doctors, pharmacists, and therapists. dailyRx, Inc. is a Patient Conversation Media, company.

SOURCE dailyRx News

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs